NewLimit
ID: 12446569NewLimit is a biotechnology company focusing on developing epigenetic reprogramming therapies that aid with illnesses that are normally associated with aging.
2
Funding Rounds
$170.0m
Money raised
Recent Funding Rounds
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
| Name | Phone | Social networks | |
|---|---|---|---|
| Bl*** By*** |
|
- | linkedin twitter |
Funding
Funding series
Funding Series Analysis
The company NewLimit has raised a total of $170m in funding over 2 rounds.
Key Insights:
- NewLimit May 2025 Series B Funding Round: $130m
- NewLimit Series A round, May 16, 2013: $40m
Industries
NewLimit is active in the following industries: